Healthcare provider profile · identity verified

Duane Oetman, M.D.

Family Practice · BYRON CENTER, MI · NPI 1417980822

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	387	106
Lisinopril	Lisinopril	303	80
Omeprazole	Omeprazole	283	77
Rosuvastatin Calcium	Rosuvastatin Calcium	282	80
Levothyroxine Sodium	Levothyroxine Sodium	279	78
Amlodipine Besylate	Amlodipine Besylate	259	69
Losartan Potassium	Losartan Potassium	212	63
Metoprolol Succinate	Metoprolol Succinate	171	44
Metformin Hcl Er	Metformin Hcl	159	38
Trazodone Hcl	Trazodone Hcl	150	44
Tamsulosin Hcl	Tamsulosin Hcl	149	40
Hydrochlorothiazide	Hydrochlorothiazide	146	40
Furosemide	Furosemide	119	32
Duloxetine Hcl	Duloxetine Hcl	117	28
Pravastatin Sodium	Pravastatin Sodium	114	30
Gabapentin	Gabapentin	103	32
Pantoprazole Sodium	Pantoprazole Sodium	94	28
Escitalopram Oxalate	Escitalopram Oxalate	85	24
Carvedilol	Carvedilol	82	22
Simvastatin	Simvastatin	81	24
Eliquis	Apixaban	78	21
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	78	22
Potassium Chloride	Potassium Chloride	73	18
Glipizide Er	Glipizide	68	17
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	64	18
Metformin Hcl	Metformin Hcl	61	18
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	57	12
Albuterol Sulfate Hfa	Albuterol Sulfate	54	27
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	52	12
Farxiga	Dapagliflozin Propanediol	51	11
Fluticasone Propionate	Fluticasone Propionate	49	20
Tramadol Hcl	Tramadol Hcl	49	14
Sertraline Hcl	Sertraline Hcl	48	14
Atenolol	Atenolol	46	12
Clopidogrel	Clopidogrel Bisulfate	46	13
Meloxicam	Meloxicam	45	13
Bupropion Xl	Bupropion Hcl	44	13
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	43	17
Dutasteride	Dutasteride	43	12
Jardiance	Empagliflozin	42	13
Pioglitazone Hcl	Pioglitazone Hcl	42	14
Finasteride	Finasteride	40	11
Glimepiride	Glimepiride	40	12
Venlafaxine Hcl Er	Venlafaxine Hcl	39	suppressed
Lovastatin	Lovastatin	37	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	36	suppressed
Alendronate Sodium	Alendronate Sodium	34	12
Paroxetine Hcl	Paroxetine Hcl	34	suppressed
Pregabalin	Pregabalin	33	12
Fenofibrate	Fenofibrate	32	suppressed
Allopurinol	Allopurinol	31	suppressed
Primidone	Primidone	31	suppressed
Ezetimibe	Ezetimibe	28	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	28	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	28	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	28	12
Doxazosin Mesylate	Doxazosin Mesylate	27	suppressed
Ozempic	Semaglutide	27	suppressed
Verapamil Er	Verapamil Hcl	27	suppressed
Xarelto	Rivaroxaban	27	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	26	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	26	suppressed
Alprazolam	Alprazolam	25	14
Diclofenac Sodium	Diclofenac Sodium	25	suppressed
Mirtazapine	Mirtazapine	25	suppressed
Spironolactone	Spironolactone	25	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	25	suppressed
Buspirone Hcl	Buspirone Hcl	23	suppressed
Famotidine	Famotidine	23	suppressed
Mounjaro	Tirzepatide	23	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	23	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	23	20
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	22	suppressed
Topiramate	Topiramate	22	suppressed
Lorazepam	Lorazepam	20	suppressed
Memantine Hcl Er	Memantine Hcl	20	suppressed
Montelukast Sodium	Montelukast Sodium	20	suppressed
Naproxen	Naproxen	20	suppressed
Ropinirole Hcl	Ropinirole Hcl	20	suppressed
Ibuprofen	Ibuprofen	19	suppressed
Myrbetriq	Mirabegron	19	suppressed
Testosterone	Testosterone	19	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	18	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	18	suppressed
Dilt-Xr	Diltiazem Hcl	17	suppressed
Valsartan	Valsartan	17	suppressed
Verapamil Sr	Verapamil Hcl	17	suppressed
Estradiol	Estradiol	16	suppressed
Glipizide	Glipizide	16	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Methimazole	Methimazole	16	suppressed
Prednisone	Prednisone	16	11
Synthroid	Levothyroxine Sodium	16	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	15	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	15	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	14	13
Clonidine Hcl	Clonidine Hcl	14	suppressed
Ipratropium Bromide	Ipratropium Bromide	14	suppressed
Lansoprazole	Lansoprazole	14	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	14	suppressed
Celecoxib	Celecoxib	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Glycopyrrolate	Glycopyrrolate	13	suppressed
Nifedipine Er	Nifedipine	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Benztropine Mesylate	Benztropine Mesylate	12	suppressed
Chlorthalidone	Chlorthalidone	12	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	12	suppressed
Glyxambi	Empagliflozin/Linagliptin	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	12
Oxybutynin Chloride Er	Oxybutynin Chloride	12	suppressed
Oxycodone Hcl	Oxycodone Hcl	12	suppressed
Terbinafine Hcl	Terbinafine Hcl	12	suppressed
Cephalexin	Cephalexin	11	suppressed
Latanoprost	Latanoprost	11	suppressed
Morphine Sulfate Er	Morphine Sulfate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error